Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | THRB | P10828 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25843065 | 0.94 | LTA4H (0.46) | LTA4HLMNAGAATHRBSMN1; SMN2 | |
| SCHEMBL10063608 | 0.87 | ALDH1A1 (0.57) | LMNAALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL8513493 | 0.87 | SIGMAR1 (0.47) | MEN1KMT2AHDAC4KCNH2HDAC1 | |
| SCHEMBL9610817 | 0.86 | ITGB3 (0.46) | LMNASMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL17920218 | 0.86 | CHKA (0.44) | LMNAGAASMN1; SMN2ALDH1A1MEN1 | |
| SCHEMBL9610831 | 0.85 | LMNA (0.53) | LMNASMN1; SMN2ALDH1A1HDAC6DRD4 | |
| SCHEMBL12732683 | 0.85 | LMNA (0.53) | LMNASMN1; SMN2ALDH1A1HDAC6DRD4 | |
| SCHEMBL2514655 | 0.84 | VEGFA (0.54) | LTA4HLMNAGAATHRBSMN1; SMN2 | |
| SCHEMBL30443787 | 0.83 | ALDH1A1 (0.43) | LMNASMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL16353103 | 0.82 | ALDH1A1 (0.46) | LMNASMN1; SMN2ALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2651411-B1 | METHODS AND COMPOSITIONS FOR IMPROVED F-18 LABELING OF PROTEINS, PEPTIDES AND OTHER MOLECULES | IMMUNOMEDICS INC (US) | 2020-09-16 | — | — | EP | disclosed |
| EP-3242691-A1 | RADIOSENSITIVITY OF FLUOROPHORES AND USE OF RADIOPROTECTIVE AGENTS FOR DUAL-MODALITY IMAGING | Immunomedics, Inc. (US) | 2017-11-15 | — | — | EP | disclosed |
| US-20170283442-A1 | Methods and Compositions for Improved F-18 Labeling of Proteins, Peptides and Other Molecules | IMMUNOMEDICS, INC. | 2017-10-05 | — | — | US | disclosed |
| US-20170283442-A1 | Methods and Compositions for Improved F-18 Labeling of Proteins, Peptides and Other Molecules | IMMUNOMEDICS, INC. | 2017-10-05 | — | — | US | disclosed |
| US-20170283442-A1 | Methods and Compositions for Improved F-18 Labeling of Proteins, Peptides and Other Molecules | IMMUNOMEDICS, INC. | 2017-10-05 | — | — | US | disclosed |
| EP-3218015-A2 | METHODS AND COMPOSITIONS FOR IMPROVED LABELING OF TARGETING PEPTIDES | Immunomedics, Inc. (US) | 2017-09-20 | — | — | EP | disclosed |
| US-20170007727-A1 | METHODS OF IMAGING WITH Ga-68 LABELED MOLECULES | IMMUNOMEDICS, INC. | 2017-01-12 | — | — | US | disclosed |
| WO-2017007807-A1 | IMPROVED METHODS OF IMAGING WITH Ga-68 LABELED MOLECULES | IMMUNOMEDICS, INC. (US) | 2017-01-12 | — | — | WO | disclosed |
| US-20170007727-A1 | METHODS OF IMAGING WITH Ga-68 LABELED MOLECULES | IMMUNOMEDICS, INC. | 2017-01-12 | — | — | US | disclosed |
| US-20170007727-A1 | METHODS OF IMAGING WITH Ga-68 LABELED MOLECULES | IMMUNOMEDICS, INC. | 2017-01-12 | — | — | US | disclosed |
| US-20140017168-A1 | Methods and Compositions for Improved F-18 Labeling of Proteins, Peptides and Other Molecules | IMMUNOMEDICS, INC. (US) | 2014-01-16 | — | — | US | disclosed |
| US-20140017168-A1 | Methods and Compositions for Improved F-18 Labeling of Proteins, Peptides and Other Molecules | IMMUNOMEDICS, INC. (US) | 2014-01-16 | — | — | US | disclosed |
| US-20140017168-A1 | Methods and Compositions for Improved F-18 Labeling of Proteins, Peptides and Other Molecules | IMMUNOMEDICS, INC. (US) | 2014-01-16 | — | — | US | disclosed |
| US-8545809-B2 | Methods and compositions for improved 18F labeling of proteins, peptides and other molecules | IMMUNOMEDICS, INC. (US) | 2013-10-01 | — | — | US | disclosed |
| US-8545809-B2 | Methods and compositions for improved 18F labeling of proteins, peptides and other molecules | IMMUNOMEDICS, INC. (US) | 2013-10-01 | — | — | US | disclosed |
| US-8545809-B2 | Methods and compositions for improved 18F labeling of proteins, peptides and other molecules | IMMUNOMEDICS, INC. (US) | 2013-10-01 | — | — | US | disclosed |
| WO-2012082618-A2 | METHODS AND COMPOSITIONS FOR IMPROVED F-18 LABELING OF PROTEINS, PEPTIDES AND OTHER MOLECULES | IMMUNOMEDICS, INC. (US) | 2012-06-21 | — | — | WO | disclosed |
| US-20120134920-A1 | Methods and Compositions for Improved F-18 Labeling of Proteins, Peptides and Other Molecules | IMMUNOMEDICS, INC. (US) | 2012-05-31 | — | — | US | disclosed |
| US-20120134920-A1 | Methods and Compositions for Improved F-18 Labeling of Proteins, Peptides and Other Molecules | IMMUNOMEDICS, INC. (US) | 2012-05-31 | — | — | US | disclosed |
| US-20120134920-A1 | Methods and Compositions for Improved F-18 Labeling of Proteins, Peptides and Other Molecules | IMMUNOMEDICS, INC. (US) | 2012-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120134920-A1 | Methods and Compositions for Improved F-18 Labeling of Proteins, Peptides and Other Molecules | F13B, FCGRT, PAICS | LTA4H 4557/4885LMNA 3399/4885GAA 654/4885 |
| US-20170007727-A1 | METHODS OF IMAGING WITH Ga-68 LABELED MOLECULES | BSG, HBG1, HBG2 | LTA4H 2150/4885LMNA 2294/4885GAA 32/4885 |
| US-20140017168-A1 | Methods and Compositions for Improved F-18 Labeling of Proteins, Peptides and Other Molecules | F13B, FCGRT, PAICS | LTA4H 4557/4885LMNA 3399/4885GAA 654/4885 |
| US-20170283442-A1 | Methods and Compositions for Improved F-18 Labeling of Proteins, Peptides and Other Molecules | F13B, PAICS, MRPL19 | LTA4H 4614/4885LMNA 3436/4885GAA 620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.